Author + information
Benefit of a scoring balloon for fibrocalcific lesions is still to be evaluated in modern drug-eluting stent (DES) era. We sought to evaluate Non Slip Element (NSE) scoring balloon for fibrocalcific lesions in a real-world population.
We identified 92 patients with de novo fibrocalcific lesions, who underwent lesion modification using NSE scoring balloon prior to second generation drug-eluting stents from January 2014 to November 2015. We performed a quantitative coronary angiography (QCA) analysis. Major adverse cardiovascular event (MACE) was defined as cardiac death, recurrent myocardial infarction, and ischemia-driven revascularization. We analyzed MACE as well as target vessel revascularization (TVR), and target lesion revascularization (TLR), and stent thrombosis at 30 days, and 9 months.
QCA analysis was shown in Table 1. Procedural success was 99.0%. MACE at 30 days, 9 months are 2.08%, and 6.2% respectively. TLR was 0% at 30days, 2.08% at 9 months. No definite stent thrombosis was noted. DESs used in the case series were either everolimus-eluting stents (89.6%) or biolimus-eluting stents (10.4%). No complication related to a NSE balloon, such as coronary dissection (>Type D) or perforation was noted.
Use of NSE scoring balloon prior 2nd generation DES is safe and excellent procedural results and confers a benefit on acute and midterm clinical outcomes for fibrocalcific lesions. In spite of higher proportion of calcific and thrombotic lesions in this case series, no definite stent thrombosis was noted. This may be partially accounted for better stent expansion and apposition.